Network-based drug repurposing for novel coronavirus 2019-nCoV/SARS-CoV-2

Abstract Human coronaviruses (HCoVs), including severe acute respiratory syndrome coronavirus (SARS-CoV) and 2019 novel coronavirus (2019-nCoV, also known as SARS-CoV-2), lead global epidemics with high morbidity and mortality. However, there are currently no effective drugs targeting 2019-nCoV/SARS-CoV-2. Drug repurposing, representing as an effective drug discovery strategy from existing drugs, could shorten the time and reduce the cost compared to de novo drug discovery. In this study, we present an integrative, antiviral drug repurposing methodology implementing a systems pharmacology-based network medicine platform, quantifying the interplay between the HCoV–host interactome and drug targets in the human…

• CC
  Cleveland Clinic
• NI
  National Institutes of Health

  Award: R00 HL138272
• NH
  National Heart, Lung, and Blood Institute

  Awards: R00 HL138272, R00HL138272, HL138272, K99HL138272, K99 HL138272